Cardio- and cerebrovascular risk with conventional synthetic disease-modifying antirheumatic drugs (CSDMARDS) in rheumatic arthritis (RA): a real-world comparative assesment - Prats-Uribe, A; Illingens, B; Vizcaya, D; Weaver, J; Burn, E; Sawant, R; Marinier, K; Ryan, P; Prieto-Alhambra, D; European Hlth Data Evidence (2020)